- Home
- HNRG vs GHRS Comparison
HNRG vs GHRS Comparison
Compare HNRG & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- GHRS
- Stock Information
- Founded
- HNRG 1949
- GHRS 2018
- Country
- HNRG United States
- GHRS Ireland
- Employees
- HNRG N/A
- GHRS N/A
- Industry
- HNRG Coal Mining
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- GHRS Health Care
- Exchange
- HNRG Nasdaq
- GHRS Nasdaq
- Market Cap
- HNRG 551.9M
- GHRS 462.0M
- IPO Year
- HNRG N/A
- GHRS 2021
- Fundamental
- Price
- HNRG $12.79
- GHRS $8.99
- Analyst Decision
- HNRG Strong Buy
- GHRS Strong Buy
- Analyst Count
- HNRG 2
- GHRS 3
- Target Price
- HNRG $15.00
- GHRS $35.67
- AVG Volume (30 Days)
- HNRG 382.2K
- GHRS 89.4K
- Earning Date
- HNRG 03-12-2025
- GHRS 02-27-2025
- Dividend Yield
- HNRG N/A
- GHRS N/A
- EPS Growth
- HNRG N/A
- GHRS N/A
- EPS
- HNRG N/A
- GHRS N/A
- Revenue
- HNRG $429,359,000.00
- GHRS N/A
- Revenue This Year
- HNRG N/A
- GHRS N/A
- Revenue Next Year
- HNRG $7.22
- GHRS N/A
- P/E Ratio
- HNRG N/A
- GHRS N/A
- Revenue Growth
- HNRG N/A
- GHRS N/A
- 52 Week Low
- HNRG $4.33
- GHRS $5.92
- 52 Week High
- HNRG $14.00
- GHRS $14.99
- Technical
- Relative Strength Index (RSI)
- HNRG 62.82
- GHRS 58.18
- Support Level
- HNRG $12.26
- GHRS $8.02
- Resistance Level
- HNRG $12.85
- GHRS $10.23
- Average True Range (ATR)
- HNRG 0.64
- GHRS 0.90
- MACD
- HNRG 0.13
- GHRS 0.11
- Stochastic Oscillator
- HNRG 85.25
- GHRS 62.20
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.